Product Pipeline

Herba's mission is to develop groundbreaking and innovative phytopharmaceutical treatments for patients with unmet medical needs. To realise our mission, we conduct clinical trials to assess the efficacy, safety, and prevention of diseases using cannabis.

Research and Partnerships

Herba Healthcare is collaborating with some of the worlds leading Universities on various commercial programs; our focus is on plant-derived cannabinoid formulations and medicine to meet unmet market needs. We are in a unique position to enter into partnerships and provide consistent and scalable cannabinoids to research institutions or Universities that will deliver commercial outcomes. We offer specific cannabinoid profiles based on your needs and meet all international safety standards and regulatory requirements.

Enquiries from interested organisations regarding grant applications or pre-clinical and clinical research are welcomed and can be made via our contact form here.

Research and Partnerships

Herba Healthcare is collaborating with some of the worlds leading Universities on various commercial programs; our focus is on plant-derived cannabinoid formulations and medicine to meet unmet market needs. We are in a unique position to enter into partnerships and provide consistent and scalable cannabinoids to research institutions or Universities that will deliver commercial outcomes. We offer specific cannabinoid profiles based on your needs and meet all international safety standards and regulatory requirements.

Enquiries from interested organisations regarding grant applications or pre-clinical and clinical research are welcomed and can be made via our contact form here.

Current development pipeline

pipeline

When a clinical trial is successful, we obtain approval from the Australian regulatory authorities to provide patients with access to these medicines via a pharmacy or hospital. Currently in Australia in certain circumstances, patients with life-threating or serious diseases who do not have access to clinical trials may utilise the access pathways supplied by the government such as the Subscriber Access Scheme B (SAS). Commonly referred to as early access or compassionate use, many countries around the world offer access to cannabis via a similar scheme.

For further information on our clinical trial program, access to medical cannabis in Australia or how you can treat your patients with our products, please contact our medical department.

When a clinical trial is successful, we obtain approval from the Australian regulatory authorities to provide patients with access to these medicines via a pharmacy or hospital. Currently in Australia in certain circumstances, patients with life-threating or serious diseases who do not have access to clinical trials may utilise the access pathways supplied by the government such as the Subscriber Access Scheme B (SAS). Commonly referred to as early access or compassionate use, many countries around the world offer access to cannabis via a similar scheme.

For further information on our clinical trial program, access to medical cannabis in Australia or how you can treat your patients with our products, please contact our medical department.

Current development pipeline

pipeline